Pliant Therapeutics Future Growth
Future criteria checks 2/6
Pliant Therapeutics is forecast to grow earnings and revenue by 16.1% and 65% per annum respectively. EPS is expected to grow by 23.2% per annum. Return on equity is forecast to be -150.6% in 3 years.
Key information
16.1%
Earnings growth rate
23.2%
EPS growth rate
| Pharmaceuticals earnings growth | 24.0% |
| Revenue growth rate | 65.0% |
| Future return on equity | -150.6% |
| Analyst coverage | Good |
| Last updated | 08 Nov 2024 |
Recent future growth updates
Recent updates
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?
Sep 13
Pliant Therapeutics: Good Data, But Will Need Watching
Sep 11Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?
Jun 07Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Feb 27Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?
Jul 21Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?
Mar 13Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Sep 10Pliant Therapeutics: Wait For A Better Price To Get In
Aug 20Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M
Aug 08Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?
Jul 28Pliant's PLN-74809 gets FDA fast track status for liver disease
Jul 21Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals
Jul 11Pliant: Major Catalyst Expected Beginning Of 2023
Jun 03We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate
Apr 22Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation
Dec 29We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth
Sep 07Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%
May 17Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 13Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans
Mar 22Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 28 | -262 | -265 | -212 | 9 |
| 12/31/2026 | 4 | -290 | -239 | -221 | 10 |
| 12/31/2025 | 6 | -258 | -209 | -197 | 12 |
| 12/31/2024 | 0 | -221 | -161 | -169 | 12 |
| 9/30/2024 | N/A | -202 | -137 | -133 | N/A |
| 6/30/2024 | N/A | -185 | -140 | -137 | N/A |
| 3/31/2024 | 0 | -171 | -119 | -116 | N/A |
| 12/31/2023 | 2 | -161 | -117 | -116 | N/A |
| 9/30/2023 | 4 | -155 | -124 | -122 | N/A |
| 6/30/2023 | 5 | -144 | -106 | -105 | N/A |
| 3/31/2023 | 10 | -133 | -106 | -104 | N/A |
| 12/31/2022 | 10 | -123 | -96 | -95 | N/A |
| 9/30/2022 | 10 | -113 | -85 | -83 | N/A |
| 6/30/2022 | 10 | -109 | -89 | -87 | N/A |
| 3/31/2022 | 7 | -103 | -85 | -82 | N/A |
| 12/31/2021 | 8 | -97 | -77 | -75 | N/A |
| 9/30/2021 | 10 | -92 | -74 | -72 | N/A |
| 6/30/2021 | 13 | -81 | -67 | -65 | N/A |
| 3/31/2021 | 15 | -75 | -40 | -38 | N/A |
| 12/31/2020 | 42 | -42 | -39 | -37 | N/A |
| 9/30/2020 | 94 | 18 | 15 | 16 | N/A |
| 6/30/2020 | 90 | 19 | 16 | 17 | N/A |
| 3/31/2020 | 86 | 20 | -6 | -5 | N/A |
| 12/31/2019 | 57 | -7 | -4 | -3 | N/A |
| 3/31/2019 | N/A | -43 | -33 | -32 | N/A |
| 12/31/2018 | N/A | -35 | -31 | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PLRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PLRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PLRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PLRX's revenue (65% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: PLRX's revenue (65% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PLRX is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 22:50 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pliant Therapeutics, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Nash | Canaccord Genuity |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |